United States Quantum Computing in Drug Discovery Market to Hit USD 191.34 Million by 2035, Driven by Accelerated Drug Development and Advancements in Molecular Simulation Technologies

The global quantum computing in drug discovery market reached US$ 126.11 million in 2025 and is expected to reach US$ 637.83 million by 2035, growing with a CAGR of 17.9% during the forecast period 2026-2035. Growth is driven by increasing demand for faster and more efficient drug discovery processes. Rising adoption of quantum computing to simulate complex molecular interactions is accelerating research capabilities. The growing need to reduce drug development time and costs is further boosting market expansion. Additionally, collaborations between pharmaceutical companies and technology providers are enhancing innovation. Continuous advancements in quantum algorithms and computing infrastructure are also supporting strong market growth.

Download PDF Sample Report:
https://www.datamintelligence.com/download-sample/quantum-computing-in-drug-discovery-market?prasad

Quantum Computing in Drug Discovery Market Major Players:

IBM
IBM is a global leader in quantum computing and a pioneer in applying quantum technologies to drug discovery. In 2025, IBM reported revenue of USD 62.0 billion, driven by its software, consulting, and infrastructure segments. In the quantum computing in drug discovery market, IBM plays a major role through its IBM Quantum platform, enabling researchers to simulate molecular interactions, optimize drug compounds, and accelerate pharmaceutical R&D. Its integration of quantum computing with AI and high-performance computing is helping reshape computational chemistry and enabling breakthroughs in complex drug modeling.

D-Wave Quantum Inc.

D-Wave Quantum is a leading company focused on quantum annealing systems and quantum cloud services. In 2025, the company reported revenue of USD 0.02 billion, reflecting its early-stage but rapidly evolving position in the quantum computing market. In the quantum computing in drug discovery market, D-Wave plays a key role by providing quantum optimization solutions that can be applied to molecular modeling, protein folding, and drug candidate selection. Its cloud-accessible quantum systems enable researchers to explore complex biological problems that are difficult to solve using classical computing methods.

Microsoft

Microsoft is a major player in quantum computing and cloud-based scientific research, with strong focus on advancing quantum applications for drug discovery. In 2025, Microsoft reported revenue of USD 110.0 billion, supported by its cloud and enterprise software segments. In the quantum computing in drug discovery market, Microsoft plays a critical role through its Azure Quantum platform, which integrates quantum hardware, software, and AI tools to support advanced research in chemistry and life sciences. Its ecosystem enables pharmaceutical companies and researchers to accelerate drug development processes and explore new therapeutic solutions.

Rigetti & Co LLC

Rigetti & Co is a specialized quantum computing company focused on superconducting quantum processors and quantum cloud services. In 2025, the company reported revenue of USD 0.03 billion, highlighting its niche but innovative position in the quantum computing ecosystem. In the quantum computing in drug discovery market, Rigetti plays a significant role by providing quantum processors and hybrid quantum-classical computing platforms used for molecular simulations and drug design optimization. Its technologies support research institutions and pharmaceutical companies in tackling complex chemical problems and accelerating next-generation drug discovery workflows.

Find the Right Partner to Accelerate Your Growth Today with Our Latest Report:
https://www.datamintelligence.com/partner-identification-enquiry/quantum-computing-in-drug-discovery-market?prasad

United States: Recent Industry Developments

✅ In March 2026, IBM Corporation expanded quantum computing applications for molecular simulation in drug discovery. The innovation improves research speed. IBM continues advancing quantum healthcare solutions.

✅ In February 2026, Google Quantum AI enhanced quantum algorithms for pharmaceutical research. The development improves compound analysis. Google continues strengthening quantum capabilities.

✅ In January 2026, Rigetti Computing expanded quantum platforms for biotech collaborations. The initiative improves drug modeling. Rigetti continues advancing quantum innovation.

✅ In December 2025, D-Wave Systems enhanced quantum optimization for pharmaceutical applications. The development improves discovery efficiency. D-Wave continues strengthening solutions.

Japan: Recent Industry Developments

✅ In March 2026, Fujitsu Limited expanded quantum-inspired computing for drug discovery applications. The innovation improves research outcomes. Fujitsu continues advancing healthcare technology.

✅ In February 2026, NEC Corporation enhanced quantum computing solutions for pharmaceutical simulations. The development improves precision. NEC continues strengthening quantum research.

✅ In January 2026, Hitachi, Ltd. expanded quantum technologies for healthcare analytics and drug discovery. The initiative improves efficiency. Hitachi continues advancing innovation.

✅ In December 2025, NTT Research enhanced quantum computing platforms for biomedical research. The development improves scalability. NTT continues strengthening quantum capabilities.

Segment Covered in the Quantum Computing in Drug Discovery Market:

By Offering: Software
Software dominates the quantum computing in drug discovery market as it enables algorithm development, molecular modeling, and simulation of complex biological systems. Most current value creation is driven by quantum-ready software platforms that integrate with classical computing to accelerate drug discovery workflows.
Software accounts for approximately 49% of the total market. Based on a global market size assumption of USD 1.3 billion in 2025, this translates to an estimated segment value of USD 0.6 billion. Growth is driven by increasing development of quantum algorithms, partnerships between pharma and tech companies, and rising demand for advanced simulation tools.

By Quantum Technology Type: Superconducting Qubits
Superconducting qubits dominate the market due to their scalability, strong industry backing, and rapid advancements by leading quantum computing companies. These systems are widely used for quantum simulations and machine learning applications in drug discovery.

This segment accounts for approximately 41% of the total market. Based on the USD 1.3 billion global market size in 2025, this corresponds to an estimated value of USD 0.5 billion. Growth is driven by increasing investments in quantum hardware, technological advancements, and expanding research collaborations.

By Drug Discovery Workflow Stage: Target Identification & Validation
Target identification & validation is the leading workflow stage as it is the foundational step in drug discovery where quantum computing can significantly improve accuracy in identifying biological targets. Quantum systems enable better molecular interaction modeling and protein structure analysis.

This segment accounts for approximately 32% of the total market. Based on the USD 1.3 billion global market size in 2025, this corresponds to an estimated value of USD 0.4 billion. Growth is driven by the need to reduce drug development timelines and improve success rates in early-stage discovery.

By Computational Application: Quantum Simulation
Quantum simulation is the dominant computational application due to its ability to model molecular and chemical interactions at an unprecedented level of accuracy. This capability is critical for understanding complex biological systems and accelerating drug discovery.

This segment accounts for approximately 37% of the total market. Based on the USD 1.3 billion market size in 2025, this translates to an estimated value of USD 0.5 billion. Growth is driven by increasing use of quantum systems for molecular modeling and drug design.

By Deployment Model: Cloud-Based
Cloud-based deployment dominates the market as it provides accessible and scalable access to quantum computing resources without the need for heavy capital investment. It enables pharmaceutical and research organizations to leverage quantum capabilities remotely.

This segment accounts for approximately 64% of the total market. Based on the USD 1.3 billion global market size in 2025, this corresponds to an estimated value of USD 0.8 billion. Growth is driven by increasing adoption of cloud platforms, collaboration between quantum providers and pharma companies, and ease of access to quantum tools.

By Therapeutic Area: Oncology
Oncology is the leading therapeutic area due to the complexity of cancer biology and the high demand for innovative drug discovery approaches. Quantum computing helps in analyzing large biological datasets and identifying novel drug candidates for cancer treatment.

This segment accounts for approximately 29% of the total market. Based on the USD 1.3 billion global market size in 2025, this corresponds to an estimated value of USD 0.4 billion. Growth is driven by increasing cancer prevalence and rising investment in oncology research.

By End-User: Pharmaceutical Companies
Pharmaceutical companies dominate the market as they are the primary investors in advanced drug discovery technologies. They are actively collaborating with quantum computing firms to accelerate R&D and improve drug development efficiency.

This segment accounts for approximately 38% of the total market. Based on the USD 1.3 billion global market size in 2025, this corresponds to an estimated value of USD 0.5 billion. Growth is driven by increasing R&D spending, strategic partnerships, and the need to reduce drug development costs and timelines.

Market Segmentation

The Quantum Computing in Drug Discovery Market is segmented by offering into hardware, software, and services; by quantum technology type into superconducting qubits, trapped-ion qubits, photonic qubits, quantum annealing, and topological qubits; by drug discovery workflow stage into target identification & validation, hit generation/lead identification, lead optimization, and preclinical candidate selection; by computational application into quantum simulation, quantum optimization, quantum machine learning, and quantum sampling; by deployment model into cloud-based and on-premises; by therapeutic area into oncology, infectious diseases, cardiovascular disorders, neurological disorders, immunological disorders, rare & orphan diseases, metabolic & endocrine disorders, and others; and by end-user into pharmaceutical companies, biopharmaceutical companies, contract research organizations (CROs), academic & research institutes, and others.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/quantum-computing-in-drug-discovery-market?prasad

Regional Analysis

North America
North America is the leading market driven by strong presence of quantum technology companies, advanced healthcare infrastructure, and high R&D investments. The region is led by the United States.

The North American market is estimated at approximately USD 0.5 billion in 2025, accounting for about 38% of the global market. Growth is driven by collaborations between quantum firms and pharmaceutical companies, along with strong government and private funding.

Europe
Europe is a significant market supported by strong research initiatives, government funding, and collaborations between academia and industry. Key contributors include Germany, France, and the United Kingdom.

The European market is valued at approximately USD 0.4 billion in 2025, representing about 31% of the global market. Growth is driven by increasing investment in quantum research and growing pharmaceutical innovation.

Asia Pacific
Asia Pacific is the fastest-growing market due to rising investments in quantum computing, expanding pharmaceutical industry, and increasing government support. Major markets include China, Japan, and India.

The region is valued at approximately USD 0.3 billion in 2025, accounting for about 23% of the global market. Growth is driven by technological advancements and increasing research collaborations.

Data-Driven Research Methodology for the Quantum Computing in Drug Discovery Market:

Our research process for the Quantum Computing in Drug Discovery Market at DataM Intelligence combines rigorous primary and secondary research to ensure accurate and reliable insights. We engage with industry experts, key stakeholders, and validated data sources to capture real-time market dynamics. Advanced analytical tools and proprietary models are applied to forecast trends, competitive landscapes, and growth opportunities. Each report undergoes multi-level validation to deliver actionable intelligence that supports strategic decision-making.

Purchase the Exclusive Report:
https://www.datamintelligence.com/buy-now-page?report=quantum-computing-in-drug-discovery-market?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us-
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us
DataM Intelligence is a market research and consulting firm that delivers comprehensive end-to-end business solutions, covering everything from in-depth research to strategic consulting. The company leverages key industry trends, insights, and developments to provide fast, reliable, and actionable solutions tailored to diverse client requirements.
It offers both syndicated and customized research reports supported by a strong and robust methodology. With an extensive database comprising 9000+ reports across 40+ industry domains, DataM Intelligence serves over 200 companies in more than 50 countries, helping organizations access critical business intelligence that drives informed decision-making and sustainable growth.

This release was published on openPR.